Biohaven's Verdiperstat, An Oral Myeloperoxidase Inhibitor, Selected For Platform Trial Collaboration At Massachusetts General Hospital's Healey and AMG Center For Amyotrophic Lateral Sclerosis (ALS)

NEW HAVEN, Conn., Sept. 18, 2019 -- (Healthcare Sales & Marketing Network) -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) ("Biohaven" or the "Company"), a clinical stage biopharmaceutical company with a portfolio of late-... Biopharmaceuticals, Neurology Biohaven Pharmaceutical, verdiperstat, Amyotrophic Lateral Sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news